1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

Characteristics of COVID-19 fatality cases in East Kalimantan, Indonesia Swandari Paramita\*, Ronny Isnuwardana, Krispinus Duma, Rahmat Bakhtiar, Muhammad Khairul Nuryanto, Riries Choiru Pramulia Yudia, Evi Fitriany, Meiliati Aminyoto Department of Community Medicine, Faculty of Medicine, Mulawarman University, Samarinda, East Kalimantan, Indonesia \*Corresponding Author: s.paramita@fk.unmul.ac.id **Abstract** Introduction Coronavirus Disease (COVID-19) is caused by SARS-CoV-2 infection. On March 2, 2020, Indonesia announced the first confirmed cases of COVID-19 infection. East Kalimantan will play an important role as the new capital of Indonesia. There is attention to the preparedness of East Kalimantan to respond to COVID-19. We report the characteristics of COVID-19 fatality cases in here. Methods We retrospectively analyzed the fatality cases of COVID-19 patients from the East Kalimantan Health Office information system. All patients were confirmed COVID-19 by RT-PCR examination. Results By July 31, 2020, 31 fatality cases of patients had been identified as having confirmed COVID-19 in East Kalimantan. The mean age of the patients was 55.1 ± 9.2 years. Most of the patients were men (22 [71.0%]) with age more than 60 years old (14 [45.2%]). Balikpapan has the highest number of COVID-19 fatality cases from all regencies. Hypertension was the most comorbidities in the fatality cases of COVID-19 patients in East Kalimantan. Discussion Older age and comorbidities still contributed to the fatality cases of COVID-19 patients in East Kalimantan, Indonesia. Hypertension, diabetes, cardiovascular disease, and cerebrovascular disease were underlying conditions for increasing the risk of COVID-19 getting into a serious condition.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Conclusion

32

35

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

- Active surveillance for people older than 60 years old and having underlying diseases is 33
- needed for reducing the case fatality rate of COVID-19 in East Kalimantan. 34
  - **Keywords**
- 36 Comorbidity, fatality cases, COVID-19, Indonesia

### Introduction

Coronavirus Disease (COVID-19) is caused by SARS-CoV-2 infection (1). In the past, there have been two epidemics of coronavirus, namely Severe Acute Respiratory Syndrome (SARS) (2), with a mortality rate of 10% (3) and Middle East Respiratory Syndrome (MERS) (4), with a mortality rate of 37% (5).

On March 11, 2020, the World Health Organization (WHO) announced the COVID-19 as a pandemic (6). During March 2020, the new major epidemic center of COVID-19 infection has been identified in Asia, Middle East, Europe, and North America. The number of confirmed cases of COVID-18 outside China had increased rapidly (7). Until July 31, 2020, the USA, Brazil, and India were the countries for the most COVID-19 cases in the world. There are more than 17 million confirmed cases worldwide (8).

On March 2, 2020, President Joko Widodo announced the first confirmed cases of COVID-19 infection in Indonesia (9). On March 18, 2020, the first patient of COVID-19 in East Kalimantan was a patient from Abdul Wahab Sjahranie Hospital Samarinda, the main referral hospital in East Kalimantan for COVID-19 (10). East Kalimantan will play a significant role as the new capital of Indonesia. There is attention to the preparedness of East Kalimantan to respond to COVID-19 (11). As of July 31, 2020, the province has reached 1,426 confirmed cases with 31 deaths (12). Therefore, the study aims to describe the characteristics of fatality cases of COVID-19 patients in East Kalimantan.

### Methods

### **Study Design**

This study was a descriptive analysis of all fatality cases of COVID-19 patients in East Kalimantan, Indonesia as of the end of July 31, 2020. This study was approved by the Ethical Health Research Commission of Faculty of Medicine Mulawarman University, Samarinda, East Kalimantan, Indonesia. All data were handled to protect patient privacy.

**Data Source** 

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

All data collected from COVID-19 fatality case records in the East Kalimantan Health Office information system through July 31, 2020. All cases were included with no sampling was done and no eligibility criteria were used.

### **Variables**

The database of patients was collected at the time of entry into the East Kalimantan Health Office information system. All confirmed cases were diagnosed based on reverse transcription-polymerase chain reaction (RT-PCR) examination to confirm COVID-19 according to guidelines from the Ministry of Health of the Republic of Indonesia.

## **Analysis**

For all cases, characteristics of patients were summarized using descriptive statistics. Continuous variables were described as a mean and standard deviation; categorical variables were described as number (%). Statistical analyses were done using Microsoft Excel.

# **Results**

By July 31, 2020, 31 fatality cases of COVID-19 patients had been identified as having laboratory-confirmed. The highest fatality cases were reaching 24 patients in July 2020. This number has rapidly increased from the last month (Figure 1). Most of the patients were men (22 [71.0%]) with age more than 60 years old (14 [45.2%]). The mean age of the patients was 55.1 ± 9.2 years. Balikpapan has the highest number of COVID-19 fatality cases patients (14 [45.2%]), but Bontang has the highest case fatality rate (4.3%) from all regencies (Table 1). Hypertension was the most comorbidities in the fatality cases of COVID-19 patients in East Kalimantan. Hypertension, diabetes, cardiovascular disease, and cerebrovascular disease were the most common underlying conditions for the fatality cases of COVID-19 patients. There were 9 (29%) patients have more than one comorbidity (Table 2).

# Table 1. Characteristics of COVID-19 fatality cases

Characteristics	Mean ± SD or N (%)
Age, years	55.1 ± 9.2
30-39 years	2 (6.5%)
40-49 years	6 (19.4%)
50-59 years	9 (29.0%)
60-69 years	13 (41.9%)
>69 years	1 (3.2%)
Sex	
Men	22 (71.0%)
Women	9 (29.0%)
Hospital admission of patients	
Province Hospital	15 (48.4%)
Regency Hospital	9 (29.0%)
Private Hospital	7 (22.6%)
Origin of patients	
Balikpapan City	14 (45.2%)
Samarinda City	11 (35.5%)
Paser Regency	2 (6.5%)
Other regencies in East Kalimantan	4 (12.9%)
CFR (Case Fatality Rate)	
East Kalimantan Province	2.2%
Bontang City	4.4%
Samarinda City	3.6%
Balikpapan City	2.8%
Berau Regency	1.3%
East Kutai Regency	1.0%
Kutai Kartanegara Regency	0.4%

# Table 2. Comorbidities of COVID-19 fatality cases

Comorbidities	
Hypertension	9 (29.0%)
Diabetes	7 (22.6%)
Cardiovascular disease	6 (19.4%)
Cerebrovascular disease	5 (16.1%)
Other comorbidities	4 (12.9%)
Number of comorbidites	
1 comorbidity	22 (71.0%)
>1 comorbidities	9 (29.0%)




Figure 1. The number of COVID-19 fatality cases in East Kalimantan (March to July 2020)

#### Discussion

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

This study reports the characteristics of 31 fatality cases of COVID-19 patients in East Kalimantan, Indonesia. As of July 31, 2020, there have been 1,426 COVID-19 positive cases in East Kalimantan (12). On that date, there are 108,376 positive confirmed cases of COVID-19, with 65,907 people recovering and 5,131 patients have died in Indonesia (13).

The progress of COVID-19 cases in March 2020 in East Kalimantan showed a total case fatality rate (CFR) of 1.85% (11). There was only one fatality case of COVID-19 patients in Samarinda in June 2020 (14). But there were already 10 fatality cases in Samarinda in July 2020. The WHO estimates that 14% of infected cases are severe and require hospitalization. Five percent of infected cases are very severe and require intensive care admission, mostly for ventilation with 4% of the infected die. COVID-19 pandemic may cause the death of 6% of the global population (15).

The mean age of the dying patients in this study was  $55.1 \pm 9.2$  years and 14 (45.2%) fatality case patients with age more than 60 years old. These results are similar to the previous retrospective cohort study in Indonesia. Data from the majority of the fatality cases, older people were associated with an increased risk of death (16). This is consistent with a study about the mortality rate of COVID-19 with a median age of 56.0 years. In-hospital death was associated with older age on admission (17).

The majority of fatality cases of COVID-19 patients in East Kalimantan are male (22) [71.0%]). This is consistent with a meta-analysis study which showed that men took the largest percentage in the distribution of COVID-19 according to gender (18). These results are similar to the previous study at Abdul Wahab Sjahranie Hospital Samarinda which showed that most patients were also male (10).

Hospital admission of 15 (48.4%) fatality case patients were in province hospital. There are 16 main referral hospitals for COVID-19 in East Kalimantan. Abdul Wahab Sjahranie Hospital in Samarinda and Kanujoso Djatiwibowo Hospital in Balikpapan are two of province hospitals in East Kalimantan. Province hospitals have more medical equipment needed for COVID-19 patients in critical condition, compared with regency or private hospitals (12).

The highest number of COVID-19 fatality case patients (14 [45.2%]) were in Balikpapan, but Bontang has the highest case fatality rate (4.3%) from all regencies. East Kalimantan has been assigned as the new capital of the Republic of Indonesia. The flow of people who came in and out of this province has increased recently. Balikpapan, Samarinda, and Bontang are

three regencies with the highest population density in East Kalimantan (11). The spread of COVID-19 depends on high population densities. Controlling infection rates is key to COVID-19 control and it depends on population densities (19).

Hypertension, diabetes, cardiovascular disease, and cerebrovascular disease were the most common underlying conditions for the fatality case of COVID-19 patients. There were 9 (29%) patients have more than one comorbidity. These results are similar to systematic review and meta-analysis study which showed that comorbidities are risk factors for severe COVID-19 patients. The most prevalent comorbidities were hypertension and diabetes, followed by cardiovascular disease (20). This is also consistent with a meta-analysis study which showed that hypertension, diabetes, cardiovascular disease, and cerebrovascular disease were risk factors associated with COVID-19 patients (21). These results are similar to the previous study at Wuhan, China which showed that underlying hypertension was significantly associated with severe COVID-19 on hospital admission. Hyperglycemia in diabetes was associated with death in patients with severe COVID-19 in Wuhan, China (22).

# Conclusion

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

Patients with older age and comorbidities need observation and early intervention to prevent the development of serious COVID-19 conditions. Active surveillance for people older than 60 years old and having underlying diseases is needed for reducing the case fatality rate of COVID-19 in East Kalimantan.

# **REFERENCES**

- Richman D, Whitley R, Hayden F. Clinical Virology. 4th ed. Washington: ASM Press; 165 1. 166 2016.
- 167 2. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt HR, Becker S, et al. 168 Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-76. 169
- WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 170 3. 31 July 2003. World Health Organization. 2003. 171
- Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a 172 4. novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 173 174 2012;367(19):1814–20.

- 175 5. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). World Health
- Organization. 2019. 176
- WHO. Novel Coronavirus China. World Health Organization. 2020. 177 6.
- 178 7. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19:
- 179 towards controlling of a pandemic. Lancet. 2020;395(10229):1015-8.
- 180 8. Worldometer. COVID-19 Coronavirus Pandemic. Worldometer. 2020.
- Djalante R, Lassa J, Setiamarga D, Mahfud C, Sudjatma A, Indrawan M, et al. Review 181 9.
- 182 and analysis of current responses to COVID-19 in Indonesia: Period of January to March
- 2020. Prog Disaster Sci. 2020;100091. 183
- 184 10. Paramita S, Isnuwardana R, Marwan M, Alfian DI, Masihoer DH. Clinical features of
- 185 COVID-19 patients in Abdul Wahab Sjahranie Hospital, Samarinda, Indonesia. medRxiv.
- 186 2020;
- 187 11. Paramita S, Rahmadi A, Isnuwardana R, Nugroho RA. One-month Progress of COVID-19
- 188 Cases in East Kalimantan, Indonesia. Open Access Maced J Med Sci. 2020;8(T1):45-50.
- Dinas Kesehatan Provinsi Kalimantan Timur. Dinas Kesehatan Provinsi Kalimantan 189 12.
- 190 Timur [Internet]. COVID-19. 2020. Available from: https://covid19.kaltimprov.go.id
- 191 13. Kementerian Kesehatan RI. Situasi Terkini Perkembangan Coronavirus Disease (COVID-
- 192 19). Kementerian Kesehatan RI. 2020.
- Paramita S, Isnuwardana R, Rahmadi A, Rafshodia O, Kusasih I. Epidemiological 193 14.
- 194 characteristics of COVID-19 patients in Samarinda, East Kalimantan, Indonesia.
- medRxiv. 2020; 195
- 196 15. Grech V. Unknown unknowns-COVID-19 and potential global mortality. Early Hum
- 197 Dev. 2020;144:105026.
- Raharusun P, Priambada S, Budiarti C, Agung E, Budi C. Patterns of COVID-19 mortality 198 16.
- 199 and vitamin D: an Indonesian study. SSRN. 2020;3585561.
- 200 17. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet.
- 201 2020;395(10229):1014-5.
- 202 18. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients' clinical
- 203 characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol.
- 204 2020;92(6):577-83.
- 205 19. Rocklöv J, Sjödin H. High population densities catalyse the spread of COVID-19. J Travel
- 206 Med. 2020;27(3):taaa038.

207 20. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the 208 novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. 209 Int J Infect Dis. 2020;

- 210 21. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049. 211
- 22. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in 212 adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-8. 213

214